Thrombophilia testing
 
Status Discontinued
Process MTA
Referral date 01 October 2000
Topic area
  • Blood and immune system
  • Cardiovascular
  • Diagnostic procedures
  • Therapeutic procedures

Provisional Schedule

Consultation on draft scope by stakeholders: June 2006
Information meeting with consultees: 11 October 2006
Closing date for invited submissions / evidence submission: 29 November 2006
Final scope published: August 2006
1st appraisal committee meeting: 30 May 2007
2nd appraisal committee meeting: 25 July 2007

Project Team

Assessment Group / Evidence Review Group: School of Health & Related Research, University of Sheffield
Communications manager: Phil Ranson
Executive Lead: Gillian Leng
Project manager: Eloise Saile
Technical Lead: Eleanor Donegan

Consultees

Manufacturers/sponsors GlaxoSmithKline (eltrombopag)
Others Department of Health
  Welsh Assembly Government
Patient/carer groups ITP Support Association
Professional groups British Society for Haematology
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians

Commentators

Associated guideline groups None
Associated public health groups None
Comparator manufacturers Roche Products (mycophenolate mofetil, rituximab)
  Sanofi-aventis (danazol)
Evidence review groups Aberdeen HTA Group
  National Institute for Health Research Health Technology Assessment Programme
General NHS Quality Improvement Scotland
Relevant research groups None

Timeline

Key events during the development of the guidance:

Date Update
13 July 2007 The Committee met on the 30 May 2007 to consider the evidence for this appraisal. On this occasion we were not able to issue an Appraisal Consultation Document (ACD) following the meeting. We will update you shortly once we have determined the best way to progress this appraisal.
July 2008 This topic has been removed from NICE’s Technology Appraisal work programme, following receipt of confirmation from Minister.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance